Serum potassium levels (K-S) are normally maintained within narrow limits (3.5-5.0 mmol / L) by multiple mechanisms. Such strict regulation is essential for numerous cellular processes. Imbalances in potassium (K) homeostasis have been associated with various pathological processes, such as the progression of heart and kidney disease and interstitial fibrosis. In addition, patients with hyperkalemia (hyperK) or hypokalemia (hypoK) have increased mortality rates. Hyperkalemia is the presence of abnormally high levels of potassium in the blood. Most data on hyperK come from hospitalized patients, in whom the incidence has been estimated to be 1% to 10%, as it is uncommon in the general population. Although there is no standard definition of hyperK, nor from what levels of KS concentration should it be treated, the European Resuscitation Council guide defines hyperK as the presence of KS levels > 5.5 mmol / L (mild hyperK: 5.5-5.9; moderate hyperK: 6.0-6.4; severe hyperK: ≥ 6.5). In order to determine whether hyperK is transient or sustained, consecutive repeated determinations should be made. HyperK is detected by blood tests, usually routine, or when disorders appear.
Patiromer; Sodium and zirconium cyclosilicate; Hyperpotassemia
Programa d'Harmonització Farmacoterapèutica. Patiròmer i ciclosilicat de sodi i zirconi per al tractament de la hiperpotassèmia. Barcelona: Servei Català de la Salut; 2021.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/6222
This item appears in following collections
The following license files are associated with this item: